Welcome to our dedicated page for iTeos Therapeutics news (Ticker: ITOS), a resource for investors and traders seeking the latest updates and insights on iTeos Therapeutics stock.
iTeos Therapeutics, Inc. (NASDAQ: ITOS) is a clinical-stage biopharmaceutical company committed to enhancing the lives of cancer patients through innovative immunotherapies. Founded in 2012 and headquartered in Gosselies, Belgium, with a research center in Watertown, Massachusetts, iTeos leverages deep insights into tumor immunology and immunosuppressive pathways to design novel product candidates.
The company's pipeline includes several promising drug candidates:
- EOS-200271: A potent and selective IDO1 inhibitor with exceptional brain penetration, currently in clinical stages.
- EOS-100850 (Inupadenant): An insurmountable adenosine A2A receptor antagonist designed to inhibit the ATP-adenosine pathway. This therapeutic candidate is in Phase 2 studies, targeting high adenosine concentrations in solid tumors.
- EOS-884448 (Belrestotug): An anti-TIGIT antibody developed to enhance the anti-tumor immune response. This candidate is being progressed in multiple indications in collaboration with GSK and is currently in Phase 1 trials.
- EOS-984: A first-in-class small molecule aimed at inhibiting the immunosuppressive activity of adenosine. This candidate is in Phase 1 development, with studies showing potential synergy with Inupadenant.
iTeos is supported by the Ludwig Institute for Cancer Research, the Walloon Region of Belgium, and the European Fund for Economic and Regional Development (FEDER). Notably, the company has secured a partnership with GSK to develop the TIGIT:PD-1 doublet therapy, which has the potential to become a leading treatment in the immuno-oncology field.
For the latest updates and detailed information, visit the 'Investors' section of their website at www.iteostherapeutics.com.
iTeos Therapeutics (Nasdaq: ITOS) has appointed David Feltquate, M.D., Ph.D., as Chief Medical Officer. Dr. Feltquate will oversee the company's clinical development and regulatory strategies. He brings nearly 20 years of experience in immuno-oncology clinical development, translational medicine, and diagnostic assay advancement.
Prior to joining iTeos, Dr. Feltquate served as Chief Medical Officer at Palleon Pharmaceuticals and held leadership positions at Novartis and Bristol Myers Squibb. Notably, he was responsible for the clinical development of the first PD-1 inhibitor at Bristol Myers Squibb. Dr. Feltquate's appointment comes at a pivotal moment for iTeos as it aims to become a leading oncology company and advance its pipeline, including its TIGIT franchise.
iTeos Therapeutics announced the dosing of the first patient in its GALAXIES Lung-301 Phase 3 trial, testing the combination of belrestotug and dostarlimab against placebo and pembrolizumab in patients with advanced PD-L1 high NSCLC. The milestone has triggered a $35 million payment from GSK, iTeos' partner. This trial is the first to evaluate the TIGIT:PD-1 doublet therapy, informed by promising interim Phase 2 results. iTeos and GSK's collaboration, established in June 2021, included a $625 million upfront payment with potential milestone payments up to $1.45 billion and a profit-sharing agreement in the US.
iTeos Therapeutics and GSK have commenced the Phase 3 GALAXIES Lung-301 study to evaluate the combination of belrestotug and dostarlimab in untreated, unresectable, locally advanced, or metastatic PD-L1 selected non-small cell lung cancer (NSCLC). This landmark study will enroll approximately 1,000 patients globally, comparing the doublet therapy to a placebo plus pembrolizumab. The study's primary endpoints include progression-free survival and overall survival. Encouraging interim results from the Phase 2 GALAXIES Lung-201 study showed significant tumor reduction and a favorable safety profile with belrestotug and dostarlimab, prompting the initiation of the Phase 3 trial.
iTeos Therapeutics, Inc. (Nasdaq: ITOS) reported positive results for the belrestotug + dostarlimab combination in lung cancer, completed successful enrollment in head and neck cancer trials, and raised $120 million in a direct offering. The company's cash balance of $715 million as of May 10, 2024, is expected to fund operations through 2027.
iTeos Therapeutics, Inc. (Nasdaq: ITOS) announced a $120 million Registered Direct Offering led by existing investors RA Capital Management and Boxer Capital. The purchase price of $17.50 per share represents a premium of approximately 44% to the last close. This offering strengthens the company's balance sheet, increasing the pro forma cash position to $715 million, extending anticipated runway through 2027.
FAQ
What is the current stock price of iTeos Therapeutics (ITOS)?
What is the market cap of iTeos Therapeutics (ITOS)?
What does iTeos Therapeutics, Inc. do?
What are the key products in iTeos' pipeline?
Where is iTeos Therapeutics headquartered?
What is EOS-200271?
What is Inupadenant (EOS-100850)?
Who are iTeos' key partners?
What is EOS-884448 (Belrestotug)?
What is EOS-984?
Where can I find the latest news about iTeos Therapeutics?
